biostudies-literaturePerrone MGUniversity of BergenItalian Association for Cancer ResearchItalian Ministero dello Sviluppo Economic (MISE, Ministry of Economic Development)The Research Council of NorwayMinistry of Economic DevelopmentFondazione G.A.I.A and Fondazione Onlus MiaNeriH2020 program MSCA-ITNFirst AIRC Grant-MFAG2015Helse Vest RHF and Helse Bergen HFThe Norwegian Cancer Society668https://www.ebi.ac.uk/biostudies/studies/S-EPMC9230671biostudies-literatureUnknown15(6)The identification and removal of all gross and microscopic tumor to render the patient disease free represents a huge challenge in ovarian cancer treatment. The presence of residual disease is an independent negative prognostic factor. Herein, we describe the synthesis and the "in vitro" evaluation of compounds as cyclooxygenase (COX)-1 inhibitors, the COX-1 isoform being an ovarian cancer biomarker, each bearing fluorochromes with different fluorescence features. Two of these compounds <i>N</i>-[4-(9-dimethylimino-9H-benzo[a]phenoxazin-5-ylamino) butyl]-2-(3,4-bis(4-methoxyphenyl)isoxazol-5-yl)acetamide chloride (RR11) and 3-(6-(4-(2-(3,4-bis(4-methoxyphenyl)isoxazole-5-yl)acetamido)butyl)amino-6-oxohexyl)-2-[7-(1,3-dihydro-1,1-dimethyl-3-ethyl 2<i>H</i>-benz[e]indolin-2-yl-idene)-1,3,5-Pharmaceuticals (Basel, Switzerland)Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes.PMC923067124022217566182735911809675743815900092223250226244911852HV1269F-12183/4800003665912171Kleinmanns KBonaccorso CVitale PBjorge LScilimati APerrone MGSolidoro RFortuna CGCentonze AMunzone CMiciaccia MFerorelli SfalseFluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes.The identification and removal of all gross and microscopic tumor to render the patient disease free represents a huge challenge in ovarian cancer treatment. The presence of residual disease is an independent negative prognostic factor. Herein, we describe the synthesis and the "in vitro" evaluation of compounds as cyclooxygenase (COX)-1 inhibitors, the COX-1 isoform being an ovarian cancer biomarker, each bearing fluorochromes with different fluorescence features. Two of these compounds <i>N</i>-[4-(9-dimethylimino-9H-benzo[a]phenoxazin-5-ylamino) butyl]-2-(3,4-bis(4-methoxyphenyl)isoxazol-5-yl)acetamide chloride (RR11) and 3-(6-(4-(2-(3,4-bis(4-methoxyphenyl)isoxazole-5-yl)acetamido)butyl)amino-6-oxohexyl)-2-[7-(1,3-dihydro-1,1-dimethyl-3-ethyl 2<i>H</i>-benz[e]indolin-2-yl-idene)-1,3,5-2022-01-01T00:00:00Z2022 May2026-04-08T10:12:34.563Z2025-04-07T00:33:17.081ZS-EPMC92306713574558710.3390/ph15060668